<DOC>
	<DOCNO>NCT00761722</DOCNO>
	<brief_summary>The purpose study compare amount drug get bloodstream different tablet take mouth injection skin .</brief_summary>
	<brief_title>Safety &amp; Pharmacokinetics Study Of Azacitidine ( SC And Oral ) In Subjects With MDS , CMML , AML , Lymphoma And Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>18 year old Diagnosis MDS CMML Diagnosis AML , Multiple myeloma , Hodgkin 's NonHodgkin 's lymphoma standard curative palliative measure exist longer effective ECOG Performance Status 02 Use acceptable birth control Standard safety inclusion serum creatinine , AST , ALT , bilirubin Serum bicarbonate great equal 20 mEq/L Platelet count great equal 25,000/uL Hemoglobin great equal 500/uL Signed inform consent Diagnosis acute promyelocytic leukemia Treatment demethylating agent within 21 day prior Cycle 1 , Day 1 Treatment anticancer therapy ( standard investigational ) within 21 day prior Cycle 1 , Day 1 ongoing adverse event previous treatment Hypersensitivity azacitidine mannitol Active , uncontrolled infection Presence GI disease , malignant tumor condition know interfere ADME Known active HIV , viral hepatitis B C Breastfeeding pregnant female Current uncontrolled cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Chronic Myelomonocytic Leukemia ( CMML )</keyword>
</DOC>